Dasatinib Is Preferentially Active in the Activated B-Cell Subtype of Diffuse Large B-Cell Lymphoma

Keyphrases

• Diffuse Large B-cell Lymphoma (DLBCL) 100%
• Activated B Cells 100%
• B Cell Subtypes 100%
• Dasatinib 100%
• Germinal Center B Cells 66%
• Multiplexing 33%
• Clinically Significant 16%
• Gene Expression Profiling 16%
• Mass Spectrometry Analysis 16%
• Mass Spectrometry 16%
• Clinical Application 16%
• NF-B 16%
• Western Blot Analysis 16%
• Lymphoma Cells 16%
• Long-term Treatment 16%
• Chemotherapy Regimen 16%
• B Cell Receptor 16%
• Worse Prognosis 16%
• Heterogeneous Disease 16%
• R-CHOP 16%
• Clinical Relapse 16%
• Cyclin-dependent Kinase 6 (CDK6) 16%
• Cyclin-dependent Kinase 4 (CDK4) 16%
• Src Kinase Inhibitor 16%
• Diffuse Large B-cell Lymphoma Cells 16%
• Cell-cycle Kinases 16%
• Active Signaling 16%
• Kinome Profiling 16%
• Aurora Kinase A (AURKA) 16%

Biochemistry, Genetics and Molecular Biology

• B Cell 100%
• Dasatinib 100%
• Gene Expression Profiling 6%
• Mass Spectrometry 6%
• Cell Cycle 6%
• Western Blot 6%
• Mass Spectrometry 6%
• B-Cell Receptor 6%
• Kinome 6%
• Aurora Kinase 6%
• Src Family Kinase 6%

Immunology and Microbiology

• B Cell 100%
• Germinal Center 26%
• Cell Cycle 6%
• Western Blot 6%
• Mass Spectrometry 6%
• Cyclophosphamide Plus Doxorubicin Plus Prednisolone Plus Rituximab Plus Vincristine 6%
• B-Cell Receptor 6%
• Diffuse Large B-Cell Lymphoma Cell Line 6%
• Kinome 6%
• Gene Expression Assay 6%